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REGULATION OF METABOLISM BY MIR-378
CROSS-REFERENCE TO RELATED
APPLICATIONS
This application is a national stage application of Interna-
tional Application No. PCT/US2011/039308, filed Jun. 6,
2011, which claimspriority to U.S. Provisional Application
Ser. No. 61/351,683, filed Jun. 4, 2010, all of which are
hereby incorporated by reference in their entireties.
DESCRIPTION OF THE TEXT FILE SUBMITTED
ELECTRONICALLY
The contents of the text file submitted electronically here-
with are incorporated herein by reference in their entirety: A
computer readable format copy ofthe Sequence Listing(file-
name: MIRG_022__01WO_SeqList_ST25 txt, date
recorded: Jun. 6, 2011, file size 5 kilobytes).
FIELD OF THE INVENTION
The present invention relates to the treatment and preven-
tion of cardiac and metabolic disorders by administering
agents that modulate the activity or expression of a
microRNA (miRNA). In particular, the invention provides a
methodfor treating or preventing cardiac and metabolic dis-
orders by inhibiting the expression or activity of miR-378/
miR-378* in cells of a subject. In addition, the invention
provides a methodfor regulating fatty acid metabolism in a
cell by contacting the cell with a modulator ofmiR-378/miR-
378* expression oractivity.
BACKGROUND OF THE INVENTION
Heart disease and its manifestations, including coronary
artery disease, myocardial infarction, congestive heart failure
and cardiac hypertrophy, clearly present a major health risk in
the United States today. The cost to diagnose, treat and sup-
port patients suffering from these diseases is well into the
billions of dollars. Two particularly severe manifestations of
heart disease are myocardial infarction and cardiac hypertro-
phy.
Myocardial infarction, commonly knownasa heart attack,
is caused by a sudden andsustained lack ofblood flow to the
heart tissue, which is usually the result of a narrowing or
occlusion of a coronary artery. Without adequate blood sup-
ply, the tissue becomes ischemic, leading to the death of
cardiomyocytes (e.g. heart muscle cells) and vascular struc-
tures. The necrotic tissue resulting from the death of the
cardiomyocytes is generally replaced by scartissue, which is
not contractile, fails to contribute to cardiac function, and
often plays a detrimental role in heart function by expanding
during cardiac contraction, or by increasing the size and
effective radius of the ventricle, for example, becoming
hypertrophic.
Cardiac hypertrophyis an adaptive responseofthe heart to
virtually all forms of cardiac disease, including those arising
from hypertension, mechanical load, myocardial infarction,
cardiac arrhythmias, endocrine disorders, and genetic muta-
tions in cardiac contractile protein genes. While the hyper-
trophic responseis initially a compensatory mechanism that
augments cardiac output, sustained hypertrophy can lead to
dilated cardiomyopathy (DCM), heart failure, and sudden
death. In the United States, approximately half a million
individuals are diagnosed with heart failure each year, with a
mortality rate approaching 50%.
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Numerous signaling pathways, especially those involving
aberrant calcium signaling, drive cardiac hypertrophy and
pathological remodeling (Heineke & Molkentin, 2006).
Hypertrophic growth in responseto stress involves different
signaling pathways and gene expression patterns than physi-
ological hypertrophy, which occurs in response to exercise.
Stress-mediated myocardial hypertrophy is a complex phe-
nomenon associated with numerous adverse consequences
with distinct molecular and histological characteristics caus-
ing the heart to fibrose, dilate and decompensate which,
through cardiomyocyte degeneration and death, often culmi-
nates in heart failure. As such, there has been intenseinterest
in deciphering the underlying molecular mechanisms and in
discovering novel therapeutic targets for suppressing adverse
cardiac growth and ultimately failure. Understanding these
mechanismsis essential to the design ofnew therapiesto treat
cardiac hypertrophy andheart failure.
Metabolic syndromeis a combination ofmedical disorders
that increase the risk of developing cardiovascular disease
and diabetes. It affects one in five people, and prevalence
increases with age. Somestudies estimate the prevalence in
the U.S. to be up to 25% of the population (Ford etal. (2002)
JAMA, Vol. 287:356-359). People afflicted with metabolic
syndromeare generally obese, sedentary, and have a certain
degree of insulin resistance. Obesity is a leading preventable
cause of death worldwide, with increasing prevalence in
adults and children, and authorities view it as one ofthe most
serious public health problemsofthe 21st century (Barness et
al. (2007) Am.J. Med. Genet. A, Vol. 143A: 3016-34). Obe-
sity can lead to reducedlife expectancy and increased health
problems, including heart disease, type 2 diabetes, sleep
apnea, certain types of cancer, and osteoarthritis. Current
therapies for metabolic syndrome and obesity focus on diet-
ing and exercise with very few effective pharmaceuticalinter-
ventions available. The effectiveness of diet and exercise in
improving these conditions varies greatly amongpatients and
tends to provide only a moderate degree of weight loss and
improvement in symptoms. Therefore, there is a need for
novel therapeutic approachesto treat metabolic disorders and
prevent the subsequent development of cardiovascular dis-
ease andheart failure.
MicroRNAshaverecently been implicated in a numberof
biological processes including regulation of developmental
timing, apoptosis, fat metabolism, and hematopoietic cell
differentiation among others. MicroRNAs (miRNAs) are
small, non-protein coding RNAs of about 18 to about 25
nucleotides in length that are derived from individual miRNA
genes, from introns of protein coding genes, or from poly-
cistronic transcripts that often encode multiple, closely
related miRNAs. See review by Carrington et al. (Science,
Vol. 301(5631):336-338, 2003). MiRNAsact as repressors of
target mRNAs by promoting their degradation, when their
sequences are perfectly complementary, or by inhibiting
translation, when their sequences contain mismatches.
MiRNAsare transcribed by RNA polymeraseII (pol II) or
RNA polymeraseIII (pol ITI; see Qi et al. (2006) Cellular &
Molecular Immunology, Vol. 3:411-419) and arise from ini-
tial transcripts, termed primary miRNAtranscripts (pri-miR-
NAs), that are generally several thousand bases long. Pri-
miRNAsare processed in the nucleus by the RNase Drosha
into about 70- to about 100-nucleotide hairpin-shaped pre-
cursors (pre-miRNAs). Following transport to the cytoplasm,
the hairpin pre-miRNAis further processed by Dicer to pro-
duce a double-strandedmiRNA. The mature miRNAstrandis
then incorporated into the RNA-induced silencing complex
(RISC), where it associates with its target mRNAs by base-
pair complementarity. In the relatively rare cases in which a
US 8,716,258 B2
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miRNA base pairs perfectly with an mRNAtarget, it pro-
motes mRNA degradation. More commonly, miRNAs form
imperfect heteroduplexes with target mRNAs, affecting
either mRNAstability or inhibiting mRNAtranslation.
Recently, signature expression patterns of miRNAsasso-
ciated with pathological cardiac hypertrophy, heart failure
and myocardial infarction in humans and mouse models of
heart disease have been identified (van Rooy et al (2006)
Proc. Natl. Acad. Sci., Vol. 103(48):18255-60; van Rooij et
al., (2007) Science, Vol. 316: 575-579). Gain- and loss-of-
function studies in mice have revealed profound and unex-
pected functions for these miRNAs in numerous facets of
cardiac biology, including the control of myocyte growth,
contractility, energy metabolism,fibrosis, and angiogenesis,
providing glimpses ofnew regulatory mechanismsandpoten-
tial therapeutic targets for heart disease. Remarkably, knock-
out mice lacking disease-inducing miRNAsare normal, but
display aberrant responses to cardiac stress, suggesting the
dedication of these miRNAs to disease-related processes
rather than tissue homeostasis, and pointing to their potential
as therapeutic targets. Thus, miRNAs represent potential
novel therapeutic targets for the development of treatments
for a variety of diseases, including cardiovascular diseases,
obesity, diabetes, and other metabolic disorders.
SUMMARYOF THE INVENTION
The present invention is based, in part, on the discovery
that the expression of miR-378 is down-regulated in heart
tissue following pressure overload and that overexpression of
miR-378 in a cardiac-specific manner exacerbates the cardiac
hypertrophic response induced by stress. Overexpression of
miR-378/miR-378* in skeletal muscle produces increased
body weight resulting from increased mass of epididymalfat
pads due to adipocyte hypertrophy and possibly adipocyte
hyperplasia. Thus, the inventors have surprisingly found that
miR-378/miR-378* regulates metabolic processes in differ-
ent tissues, including cardiac and adipose tissue. Accord-
ingly, the present invention provides methodsoftreating or
preventing cardiovascular disease and other metabolic disor-
ders, such as obesity and diabetes, by modulating the expres-
sion or activity of miR-378 and/or miR-378* in cells in a
subject in need thereof.
In one embodiment, the present invention provides a
methodoftreating or preventing pathologic cardiac hypertro-
phy, cardiac remodeling, myocardial infarction, or heart fail-
ure in a subject in need thereof comprising administering to
the subject an inhibitor of miR-378 and/or miR-378*. In
certain embodiments, the expression or activity of miR-378
and/or miR-378* is reduced in the heart cells of the subject
following administration. In other embodiments, the stress-
induced metabolic shift from oxidative to glycolytic metabo-
lism is prevented or reduced in heart cells of the subject
following administration of the miR-378 and/or miR-378*
inhibitor.
The presentinvention also includes a methodoftreating or
preventing a metabolic disorder in a subject in need thereof.
In one embodiment, the method comprises administering to
the subject an inhibitor of miR-378 and/or miR-378*,
wherein the expression or activity of miR-378 and/or miR-
378* is reduced in the cells of the subject following admin-
istration. The metabolic disorder to be treated can include
metabolic syndrome, obesity, diabetes mellitus, diabetic
nephropathy, insulin resistance, atherosclerosis, a lipid stor-
age disorder, a glycogen storage disease, medium-chain acyl-
coenzyme A dehydrogenase deficiency, lipid oxidation, or
aberrant glucose uptake and/or utilization. Secondary dis-
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eases or conditions resulting from these metabolic disorders
can also be prevented or treated with the methods of the
invention. For example, in one embodiment, the invention
provides a method of preventing or treating secondary dis-
easesor disorders resulting from obesity, such as sleep apnea,
cancer, and osteoarthritis, by administering an inhibitor of
miR-378 and/or miR-378*.
The miR-378 and miR-378* inhibitors suitable for use in
the methods of the invention can be antisense oligonucle-
otides. In one embodiment, the antisense oligonucleotide
comprises a sequencethatis at least partially complementary
to a mature sequence of miR-378 or miR-378*. In certain
embodiments,the antisense oligonucleotides comprise one or
moresugarorbackbone modifications, such as locked nucleic
acids, bicyclic nucleosides, phosphonoformates, 2' O-alkyl
modifications, and phosphorothioate linkages. In other
embodiments, the miR-378 or miR-378* inhibitor is an anti-
sense oligonucleotide of about 7 to about 18 nucleotides in
length.
In another embodiment, the present invention provides a
methodofregulating fatty acid metabolism in a cell compris-
ing contacting the cell with a modulator of miR-378 and/or
miR-378* expression or activity. The modulator can be an
inhibitor or agonist ofmiR-378 and/or miR-378* expression
or activity. In certain embodiments, fatty acid metabolism is
increased in the cell following contact with a miR-378 and/or
miR-378* inhibitor as comparedto a cell not exposed to the
inhibitor. In other embodiments, fatty acid metabolism is
decreased in the cell following contact with the miR-378
and/or miR-378* agonist as comparedto a cell not exposed to
the agonist. The cell may be in vitro or in vivo. In some
embodiments,the cell is a cardiomyocyte, a skeletal muscle
cell, a preadipocyte, an adipocyte, a hepatocyte, or a pancre-
atic cell.
Thepresent invention also includes a methodofregulating
cardiac metabolism. In one embodiment, the method com-
prises contacting a cardiomyocyte with a modulator ofmiR-
378 and/or miR-378* expressionor activity. The cardiomyo-
cyte can be in vitro or in vivo. In another embodiment,
carbohydrate metabolism is reduced in the cardiomyocyte
following contact with a miR-378 and/or miR-378* inhibitor.
In still another embodiment, fatty acid metabolism is
increasedinthe cardiomyocyte following contact with a miR-
378 and/or miR-378* inhibitor.
The present invention encompasses pharmaceutical com-
positions comprising the miR-378 and miR-378* inhibitors
and agonists described herein and a pharmaceutically accept-
able carrier. In one embodiment, the pharmaceutical compo-
sition comprises an inhibitor of miR-378 and/or miR-378*
and a pharmaceutically acceptable carrier, wherein the inhibi-
tor is an antisense oligonucleotide. In certain embodiments,
the antisense oligonucleotide comprises at least one sugar
and/or backbone modification. In other embodiments, the
antisense oligonucleotide is about 7 to about 18 nucleotides in
length.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1. A. Genomic location of miR-378 within the host
gene PPARGC16 (top). UCSC Genome Browserillustration
of the conservation of the genomic region surrounding miR-
378 (bottom). B. Quantitative real-time PCR analysis shows
that miR-378, miR-378*, and PPARGC1B (PGC-1), the
host gene ofmiR-378/miR-378* are specifically expressed in
heart, skeletal muscle and brown adiposetissue. C. miR-378
is more highly expressed in cardiomyocytes than in cardiac
fibroblasts. D. miR-378 expression is reduced upontreatment
US 8,716,258 B2
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ofHIB1Bcells with stearic acid. E. miR-378 and PPARGC1B
(PGC-18) expression during induction of adipocyte differen-
tiation. CMC: cardiomyocytes, BAT: brown adiposetissue,
WAT:white adipose tissue.
FIG. 2. A. MiR-378 is down-regulated in the heart upon
thoracic aortic banding (TAB) compared to untreated heart
(sham controls) as shown by quantitative realtime PCR.B.
Myocardial overexpression of miR-378 induces an exacer-
bated hypertrophic response upon TAB.
FIG. 3. Overexpression ofmiR-378 in the skeletal muscle
results in increasedbody weight and epididymalfat mass. Top
panels show histological analysis of white fat tissue from
wild-type (WT) mice and mice overexpressing miR-378
under the control ofthe MCK promoter (MCK-miR-378 Tg).
Mutant animals display hypertrophic adipocytes. Lower pan-
els show increased body weight and increased white fat mass
in the MCK-miR-378 transgenic mice comparedto wild-type
mice.
FIG. 4. Overexpression of miR-378 in 3T3-L1 cells
enhances adipogenesis and lipogenesis. 313-L1 cells were
induced to differentiate into mature adipocytes for 4 days.
Transfection ofmiR-378 increased the accumulation oflipids
within the cells, as demonstrated by Oil red O staining.
FIG. 5. MCK-miR-378 transgenic mice exhibit reduced
glucose tolerance. Mice expressing miR-378 under the con-
trol of the muscle creatine kinase (MCK) promoter (Tg) or
wild-type littermates (wt) were injected i.p. with 1.5 g/kg
glucose after being fasted for 16 hours. Blood glucoselevels
were assessedat the indicated time points.
FIG. 6. AntimiR-378 injection in MCK-miR-378 trans-
genic mice improves glucose clearance. Mice expressing
miR-378 under the control of the muscle creatine kinase
(MCK)promoter (Tg) were injected 1.v. on three consecutive
days with 10 mg/kg of an antisense oligonucleotide having a
sequence complementary to the miR-378 mature sequence
(antmiR). Wild-type (wt) mice were injected with saline.
Both Tg and wt mice were subsequently injected i.p. with 1.5
g/kg glucose after being fasted for 16 hours. Blood glucose
levels were assessedat the indicated time points (left panel).
Real-time PCR analysis for miR-378 expression in Tg and wt
mice injected with antimiR-378or saline (right panels).
FIG. 7. AntimiR-378 injection in ob/ob mice improves
glucose clearance. Obese mice (ob/ob) were injected i.v. on
three consecutive days with 10 mg/kg of an antisense oligo-
nucleotide having a sequence complementary to the miR-378
mature sequence (antmiR). Untreated and antimiR-treated
ob/ob mice were injected i.p. with 1.5 g/kg glucose after
being fasted for 16 hours. Blood glucoselevels were assessed
at the indicated time points.
FIG. 8. A. MiR-378 targeting strategy. A targeting con-
struct was introduced into the genomic miR-378locus,yield-
ing homologous recombination. B. Southern blot analysis of
wild-type (WT) and targeted ES cells (MUT). C. Northern
blot analysis performed using total RNA from wild-type
(+/+), heterozygote (+/-), and knockout (-/-) mice shows
that miR-378 expression (arrow) is abolished in the mutant
mouse line generated. H: heart, BAT: brown adiposetissue,
Sk.M:skeletal muscle. D. Real time PCR (left panel) and
Western blot analysis (right panel) of heart tissue isolated
from WT and miR-378 knockout (KO) mice shows that
expression ofthe miR-378 host gene, PPARGC1 (PGC-16),
is not significantly altered in miR-378 knockout animals.
FIG. 9. MiR-378 knockout animals exhibit reduced cardiac
hypertrophy in responseto thoracic aortic banding (TAB).
FIG. 10. Echocardiography was performed in wild-type
(WT) and miR-378 knockout (KO) mice 21 days after tho-
racic aortic banding (TAB) to determine fractional shortening
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(A), ejection fraction (B), systolic diameter (C), and diastolic-
systolic diameter (DD-SD)(D).
FIG. 11. Expression of stress-induced genes, BNP (A),
Myh7 (B), and Myhé6(C), in heart tissue of wild-type (WT)
and miR-378 knockout (KO) mice following thoracic aortic
banding (TAB)as assessed by real time PCR.
FIG. 12. Obese mice (ob/ob) were crossed with miR-378
knockout animals to obtain obese mice lacking expression of
miR-378 (ob/ob KO). Obese mice and the ob/ob KO mice
were injected i.p. with 1.5 g/kg glucoseafter being fasted for
16 hours. Blood glucose levels were assessed atthe indicated
time points.
FIG. 13. A. MiR-378 knockout (KO) mice exhibit less
body weight gain than wild-type (WT) animals after several
weeks ona high fat diet. B. After five weeks on a high fatdiet,
both miR-378 knockout and wild-type mice were injected 1-p.
with 1.5 g/kg glucose after being fasted for 16 hours. Blood
glucose levels were assessed at the indicated time points.
FIG. 14. MiR-378 knockout (KO) mice have reduced fat
pads and hepatic lipid accumulation than wild-type (WT)
animalsafter six weeks ona high-fat diet. WAT: white adipose
tissue.
FIG. 15. MiR-378 knockout (KO) mice have reduced fat
massafter six weeks on a high-fat diet as compared to wild-
type (WT) animals. BAT: brown adiposetissue; WAT: white
adiposetissue.
FIG. 16. Histological analysis of white adipose tissue
(WAT), brown adipose tissue (BAT), andliver from wild-type
(WT) mice and miR-378 knockout (KO) mice following six
weeks of a high-fat diet regimen. Magnification: 40x.
FIG. 17. Mice overexpressing miR-378/miR-378*in heart
tissue under the control of the alpha-myosin heavy chain
promoter (a-MHC TG) have increased body weight (A) and
exhibit a greater increase in body weight on a highfat diet (B
and C) as compared to wild-type (WT)littermates.
FIG. 18. A. Western blot analysis of brown adiposetissue
isolated from wild-type (WT) and miR-378 knockout (KO)
six hours after fasting. Blots were probed with antibodies
specific for the phosphorylated and non-phosphorylated
forms ofAMPK and AKT.Alpha-tubulin was used as a con-
trol. B. Schematic showing regulation of metabolism by
AMPKandAKTsignaling pathways.
FIG. 19. A. Schematic of 3' UTR ofMED13 depicting the
putative binding sites for miR-378/miR-378*. B. Expression
levels of MED13 in wild-type (WT), miR-378 transgenics
overexpressing miR-378 under the control of the aMHC
promoter (aMHCTg), and miR-378 knockout (KO) animals.
C. COS1 cells were transfected with a MED13 3'UTR
luciferase construct, along with expression plasmids formiR-
378 and a control miRNA. Values shown are fold-change in
luciferase expression (tSEM) comparedto the reporter alone.
DETAILED DESCRIPTION OF THE INVENTION
Chronic and acutestressto the heart results in a pathologi-
cal remodeling response accompanied by hypertrophy, fibro-
sis, myocyte apoptosis and eventual death from pumpfailure
and arrhythmias. While classical pharmacological treatment
strategies (e.g. beta-blockers and ACE-inhibitors) can pro-
long survival in heart failure patients, these therapies are
ultimately ineffective in preventing progression of the dis-
ease, underscoring the need for new mechanistic insights and
therapeutic approaches.
Heart failure is a progressive long-term diseasethat affects
an estimated 5.7 million Americans with increasing associ-
ated healthcare costs (Lloyd-Jones et al. (2009) Circulation,
Vol. 119:21-181). MiRNAshave recently emerged as impor-
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tant molecular components in hypertrophy and remodeling in
the heart, thus representing a promising target in the preven-
tion and treatment of heart disease. Because individual miR-
NAsoften regulate the expression of multiple target genes
with related functions, modulating the expression of a single
miRNAcan, in principle, influence an entire gene network
and thereby modify complex disease phenotypes.
Thepresent invention is based, in part, on the discovery of
a miRNAthat is highly expressed in the mitochondrial-rich
tissues ofthe heart, skeletal muscle, and brown adipose and is
regulated in various cardiac disease states. In particular, the
inventors have surprisingly discovered that miR-378 andits
counterpart minor sequence, miR-378*, are regulators ofglo-
bal metabolism. MiR-378 playsa role in the stress-induced
cardiac hypertrophic response through the regulation of car-
diac metabolism and is implicated in glucose utilization and
fatty acid metabolism in skeletal muscle. Accordingly, the
present invention provides a methodofpreventing or treating
various cardiac and metabolic disorders in a subject by inhib-
iting the expression or activity ofmiR-378 and/or miR-378*
in cells of the subject.
As usedherein,the term “subject”or “patient” refers to any
vertebrate including, without limitation, humans and other
primates (e.g., chimpanzees and other apes and monkey spe-
cies), farm animals (e.g., cattle, sheep, pigs, goats and
horses), domestic mammals(e.g., dogs and cats), laboratory
animals(e.g., rodents such as mice,rats, and guinea pigs), and
birds (e.g., domestic, wild and gamebirds such as chickens,
turkeys and other gallinaceous birds, ducks, geese, and the
like). Insome embodiments, the subject is amammal. In other
embodiments, the subject is a human.
MiR-378 is encoded on murine chromosome18, within the
first intron of the Peroxisomeproliferator-activated receptor
gamma coactivator 1-beta (PPARGC1B) gene. In humans,
miR-378 (previously named miR-422b) is expressed from the
first intron of the PPARGC16 gene on chromosome 5. The
pre-miRNA sequence for miR-378is processed into a mature
sequenceanda star (i.e. minor) sequence. The star sequence
is processed from the other arm of the stem loop structure.
The pre-miRNA(e.g. stem-loop sequences), mature, and star
sequences for mouse and human miR-378are given below:
Human mature miR-378
(SEQ ID NO: 1)
5'- ACUGGACUUG GAGUCAGAAG G-3!
Human miR-378*
(SEQ ID NO: 2)
5'- CUCCUGACUC CAGGUCCUGU GU-3!
Human pre-miR-378
(SEQ ID NO: 3)
5'- AGGGCUCCUG ACUCCAGGUC CUGUGUGUUA CCUAGAAAUA
GCACUGGACU UGGAGUCAGA AGGCCU-3'!
Mouse mature miR-378
(SEQ ID NO: 4)
5'-ACUGGACUUG GAGUCAGAAG G-3!'
Mouse miR-378*
(SEQ ID NO: 5)
5'- CUCCUGACUC CAGGUCCUGU GU-3!
Mouse pre-miR-378
(SEQ ID NO: 6)
5'- AGGGCUCCUG ACUCCAGGUC CUGUGUGUUA CCUCGAAAUA
GCACUGGACU UGGAGUCAGA AGGCCU-3'!
10
15
20
25
30
35
40
45
50
55
60
65
8
It is understood that all ribonucleic acid sequences dis-
closed herein can be converted to deoxyribonucleic acid
sequences by substituting a thymidine base for a uridine base
in the sequence. Likewise, all deoxyribonucleic acid
sequences disclosed herein can be converted to ribonucleic
acid sequences by substituting a uridine base for a thymidine
base in the sequence. Deoxyribonucleic acid sequences, ribo-
nucleic acid sequences, and sequences containing mixtures of
deoxyribonucleotides and ribonucleotides of all sequences
disclosed herein are includedin the invention.
In one embodiment, the present invention provides a
methodoftreating or preventing pathologic cardiac hypertro-
phy, cardiac remodeling, myocardial infarction, or heart fail-
ure in a subject in need thereof comprising administering to
the subject an inhibitor ofmiR-378 and/ormiR-378*. In some
embodiments, the expression or activity of miR-378 and/or
miR-378* is reducedinthe heart cells ofthe subject following
administration of the inhibitor. “Heart cells,’ as used herein,
include cardiomyocytes, cardiac fibroblasts, and cardiac
endothelial cells. In one particular embodiment, the expres-
sion or activity of miR-378 and/or miR-378* is reduced in
cardiomyocytesofthe subject following administration ofthe
miR-378 and/or miR-378* inhibitor.
In another embodiment, the subject in need thereofmay be
at risk for developing pathologic cardiac hypertrophy, cardiac
remodeling, heart failure, or myocardial infarction. Such a
subject may exhibit one or morerisk factors including, but not
limited to, long standing uncontrolled hypertension, pulmo-
nary arterial hypertension, uncorrected valvular disease,
chronic angina, recent myocardial infarction, congenital pre-
disposition to heart disease or pathological hypertrophy. The
subject at risk may be diagnosed as having a genetic predis-
position to cardiac hypertrophy or may havea familial history
of cardiac hypertrophy. In some embodiments, the subject at
risk may be diagnosed with obesity, type II diabetes, hyper-
lipidemia, or metabolic syndrome.
Preferably, administration ofan inhibitor ofmiR-378 and/
or miR-378* to the subject results in the improvementofone
or more symptomsofcardiac hypertrophy, heart failure, or
myocardial infarction in the subject, or in the delay in the
transition from cardiac hypertrophyto heart failure. The one
or more improved symptoms maybe, for example, increased
exercise capacity, increased cardiac ejection volume,
decreased left ventricular end diastolic pressure, decreased
pulmonary capillary wedge pressure, increased cardiac out-
put, increased cardiac index, lowered pulmonary artery pres-
sures, decreased left ventricular end systolic and diastolic
dimensions, decreased cardiac fibrosis, decreased collagen
deposition in cardiac muscle, decreased left and right ven-
tricular wall stress, decreased wall tension, increased quality
of life, and decreased disease-related morbidity or mortality.
The present invention also includes a methodoftreating or
preventing a metabolic disorder in a subject in need thereof.
In one embodiment, the method comprises administering to
the subject an inhibitor of miR-378 and/or miR-378*,
wherein the expression or activity of miR-378 and/or miR-
378* is reduced in the cells of the subject following admin-
istration. The metabolic disorders that can be treated with the
methods of the invention include, but are not limited to,
metabolic syndrome, obesity, diabetes mellitus, diabetic
nephropathy, insulin resistance, atherosclerosis, a lipid stor-
age disorder(e.g., Niemann-Pick disease, Gaucher’s disease,
Farber disease, Fabry disease, Wolman disease, and choles-
teryl ester storage disease), polycystic ovarian syndrome
(PCOS), or aberrant glucose uptake and/orutilization. In one
embodiment, the metabolic disorder is a glycogen storage
disease (GSD). For instance, the methods of the invention
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provide treating or preventing any of the types of GSD(e.g.,
GSDtype 0 and GSD type I to GSD type XII) ina subject in
need thereofby administering to the subject a miR-378 and/or
miR-378* inhibitor. GSDs include,but are not limited to, von
Gierke’s disease, Pompe’s disease, Cori’s disease or Forbes’
disease, Andersen disease, McArdle disease, Hers’ disease,
Tarui’s disease, Fanconi-Bickel syndrome,andred cell aldo-
lase deficiency. In another embodiment, the metabolic disor-
der is medium-chain acyl-coenzyme A dehydrogenase
(MCAD)deficiency. Individuals having MCAD deficiency
exhibit an impairmentin fatty acid oxidation thatcan be fatal.
In one embodimentofthe invention,fatty acid metabolism is
increased in subject’s having MCADdeficiency following
administration of a miR-378 and/or miR-378* inhibitor.
Thepresent invention also includes a methodofpreventing
or treating secondary diseases or conditions resulting from
metabolic disorders, such as diabetes and obesity, by admin-
istering to a subject in need thereofofan inhibitor ofmiR-378
and/or miR-378*. For example, in one embodiment, the
invention provides a method of preventing or treating sleep
apnea comprising administering to a subject in need thereof
an inhibitor ofmiR-378 and/or miR-378*. In another embodi-
ment, the invention provides a methodofpreventingortreat-
ing cancer by administering to a subject in need thereof an
inhibitor of miR-378 and/or miR-378*. In still another
embodiment, the invention provides a method of preventing
or treating osteoarthritis by administering to a subject in need
thereof an inhibitor of miR-378 and/or miR-378*.
In another embodiment, the present invention encom-
passes a method of increasing glucose uptake and/orutiliza-
tion in a subject in need thereof comprising administering to
the subject an inhibitor ofmiR-378 and/or miR-378* activity
or expression. In some embodiments, the subject is diagnosed
with insulin resistance or diabetes mellitus. In one embodi-
ment, the subject’s blood glucose level is reduced following
administration of the miR-378 and/or miR-378* inhibitor as
compared to the blood glucose level of the subject prior to
administration of the inhibitor. In another embodiment, the
subject’s blood glucose level is reduced to within normal
levels as measured by the oral glucose tolerance test follow-
ing administration ofthe miR-378 and/or miR-378* inhibitor.
For instance, in certain embodiments, the subject’s fasting
blood glucose level is less than about 110 mg/dl. In other
embodiments, the subject’s blood glucose level 2 hours post
glucose ingestion is less than about 140 mg/dl.
The present invention also provides a method ofregulating
fatty acid metabolism in a cell. In one embodiment, the
method comprises contacting the cell with a modulator of
miR-378 and/or miR-378* expression or activity. As used
herein, a “modulator”is a molecule that regulates the expres-
sion or activity ofmiR-378 and/or miR-378*. Modulators can
be agonists of miR-378 and/or miR-378* function (ie.
enhancethe activity or expression ofmiR-378 or miR-378*)
or they can be inhibitors of miR-378 and/or miR-378* func-
tion (i.e. reduce the activity or expression of miR-378 or
miR-378*). Modulators can include proteins, peptides,
polypeptides, polynucleotides, oligonucleotides, or small
molecules. Modulators ofmiR-378 and/or miR-378* expres-
sion or activity include miR-378 and/or miR-378* inhibitors
and agonists as described herein. In certain embodiments, the
modulator is an inhibitor of miR-378 and/or miR-378*
expression or activity, and fatty acid metabolism is increased
in the cell following contact with the miR-378 and/or miR-
378* inhibitor as comparedto a cell not exposedto the inhibi-
tor. In other embodiments, the modulator is an agonist of
miR-378 and/or miR-378* expression or activity, and fatty
acid metabolism is decreased in the cell following contact
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with the miR-378 and/or miR-378* agonist as compared to a
cell not exposed to the agonist. The cell can be in vitro or in
vivo. In some embodiments,the cell is, but is not limited to, a
cardiomyocyte, a skeletal muscle cell, a preadipocyte, an
adipocyte, a hepatocyte, or a pancreatic cell.
In one particular embodiment, the cell is a cardiomyocyte.
Thus, the present invention also encompasses a method of
regulating cardiac metabolism by contacting a cardiomyo-
cyte with a modulator of miR-378 and/or miR-378* expres-
sion or activity. In one embodiment, contacting the cardi-
omyocyte with a miR-378 and/or miR-378* inhibitor
prevents or reduces the metabolic shift from oxidative
metabolism to glycolytic metabolism inducedby astressor. In
another embodiment, contacting the cardiomyocyte with a
miR-378 and/or miR-378* inhibitor reduces carbohydrate
metabolism in the cardiomyocyte. In still another embodi-
ment, contacting the cardiomyocyte with a miR-378 and/or
miR-378* inhibitor increases fatty acid metabolism in the
cardiomyocyte. The cardiomyocyte can bein vitro or in vivo.
In another aspect, the present invention encompasses a
method of regulating mitochondrial dysfunction in a cell by
contacting the cell with a modulator ofmiR-378 and/or miR-
378* expression or activity. In one embodiment, contacting
the cell with a miR-378 and/or miR-378* inhibitor increases
mitochondrial biogenesis in the cell as compared to an
untreated cell. In another embodiment, contacting the cell
with a miR-378 and/or miR-378* inhibitor enhances mito-
chondrial fatty acid oxidation in the cell as compared to an
untreated cell. In yet another embodiment, contacting the cell
with a miR-378 and/or miR-378* agonist enhances lipogen-
esis in the cell as comparedto anuntreated cell. In still another
embodiment, contacting the cell with a miR-378 and/or miR-
378* agonist enhances glucose metabolism in the cell as
compared to an untreated cell. The cell can be in vitro or in
vivo. In certain embodiments, the cell is, but is not limited to,
a cardiomyocyte, a skeletal muscle cell, a preadipocyte, an
adipocyte, a hepatocyte, or a pancreatic cell.
The present invention also provides a method for prevent-
ing or treating disorders or diseases associated with a defi-
ciency in glycolytic or fatty acid metabolism.For instance, in
one embodiment, the present invention provides a method for
preventing or treating hypoglycemia or hyperinsulinism in a
subject in need thereof by administering to the subject a
miR-378 and/or miR-378* agonist. Subjects at risk of devel-
oping hypoglycemia or hyperinsulinism include diabetic
patients who overdose on insulin or certain diabetes medica-
tions (e.g., chlorpropamide, tolazamide, acetohexamide,
glipizide, or tolbutamide), subject who havean insulin secret-
ing tumor(insulinoma), patients diagnosed with liver disease
or genetic conditions that cause hyperinsulinism. Other dis-
orders or conditions that may be treated or prevented with
agonists of miR-378 and/or miR-378* are those in which
patients have difficulty maintaining a normal body weight or
experience unintentional weight loss. For instance, in one
embodiment, the present invention includes a methodoftreat-
ing or preventing hyperthyroidism (Graves’ Disease) in a
subject in need thereof by administering to the subject a
miR-378 and/or miR-378* agonist.
In some embodiments, an inhibitor of miR-378 and/or
miR-378* is an antisense oligonucleotide. The antisenseoli-
gonucleotides can include ribonucleotides or deoxyribo-
nucleotides or a combination thereof. Preferably, the anti-
sense oligonucleotides have at least one chemical
modification (e.g., sugar or backbone modification). For
instance, suitable antisense oligonucleotides can be com-
prised of one or more “conformationally constrained” or
bicyclic sugar nucleoside modifications (BSN) that confer
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enhanced thermalstability to complexes formed between the
oligonucleotide containing BSN and their complementary
microRNAtarget strand. For example, in one embodiment,
the antisense oligonucleotides contain at least one “locked
nucleic acid.” Locked nucleic acids (LNAs) contain the 2'-O,
4'-C-methylene ribonucleoside (structure A) wherein the
ribose sugar moiety is in a “locked” conformation.In another
embodiment, the antisense oligonucleotides contain at least
one 2', 4'-C-bridged 2' deoxyribonucleoside (CDNA,struc-
ture B). See, e.g., U.S. Pat. No. 6,403,566 and Wangetal.
(1999) Bioorganic and Medicinal Chemistry Letters, Vol. 9:
1147-1150, both of which are herein incorporated by refer-
ence in their entireties. In yet another embodiment, the anti-
sense oligonucleotides contain at least one modified nucleo-
side having the structure shownin structure C. The antisense
oligonucleotides targeting miR-378 can contain combina-
tions of BSN (LNA, CDNAandthelike) or other modified
nucleotides, and ribonucleotides or deoxyribonucleotides.
 
Alternatively, the antisense oligonucleotides can comprise
peptide nucleic acids (PNAs), which contain a peptide-based
backbone rather than a sugar-phosphate backbone. Other
modified sugar or phosphodiester modifications to the anti-
sense oligonucleotide are also contemplated. For instance,
other chemical modifications that the antisense oligonucle-
otides can contain include, but are not limited to, sugar modi-
fications, such as 2'-O-alkyl (e.g. 2'-O-methyl, 2'-O-meth-
oxyethyl), 2'-fluoro, and 4' thio modifications, and backbone
modifications, such as one or more phosphorothioate, mor-
pholino, or phosphonocarboxylate linkages (see, for
example, U.S. Pat. Nos. 6,693,187 and 7,067,641, which are
herein incorporated by reference in their entireties). In one
embodiment, antisense oligonucleotides targeting miR-378
or miR-378* contain 2'0-methyl sugar modifications on each
base and are linked by phosphorothioate linkages. Antisense
oligonucleotides, particularly those of shorter lengths (e.g.,
less than 15 nucleotides) can comprise one or moreaffinity
enhancing modifications, such as, but not limited to, LNAs,
bicyclic nucleosides, phosphonoformates, 2' O-alkyl modifi-
cations andthelike. In some embodiments,suitable antisense
oligonucleotides are 2'-O-methoxyethyl “gapmers” which
contain 2'-O-methoxyethy]-modified ribonucleotides on both
5' and 3' ends with at least ten deoxyribonucleotides in the
center. These “gapmers” are capable of triggering RNase
H-dependent degradation mechanisms ofRNAtargets. Other
modifications of antisense oligonucleotides to enhancesta-
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bility and improveefficacy, such as those described in U.S.
Pat. No. 6,838,283, whichis herein incorporated by reference
in its entirety, are knownin the art and are suitable for use in
the methodsofthe invention. For instance,to facilitate in vivo
delivery andstability, the antisense oligonucleotide can be
linked to a steroid, such as cholesterol moiety, a vitamin, a
fatty acid, a carbohydrate or glycoside, a peptide, or other
small molecule ligandat its 3' end.
Preferable antisense oligonucleotides useful for inhibiting
the activity ofmiRNAsare about 5 to about 25 nucleotides in
length, about 10 to about 30 nucleotidesin length, or about 20
to about 25 nucleotides in length. In certain embodiments,
antisense oligonucleotides targeting miR-378 and/or miR-
378* are about 7 to about 18 nucleotides in length, and in
other embodiments about 12 to about 16 nucleotides in
length. Any 7-mer or longer complementary to miR-378 or
miR-378* may be used, i.e., any antimiR complementary to
the 5' end of the miRNA and progressing across the full
complementary sequence ofthe miRNA.Forinstance, in one
embodiment,the antisense oligonucleotide has a sequence of
5'-CCUUCUGACUCCAAGUCCAGU-3' (SEQ ID NO:7).
In another embodiment, the antisense oligonucleotide has a
sequence of 5'-AGUCCAGU-3' (SEQ ID NO:8). In another
embodiment,the antisense oligonucleotide has a sequence of
5'-CAAGUCCAGU-3' (SEQ ID NO:9). In another embodi-
ment, the antisense oligonucleotide has a sequence of 5'-UC-
CAAGUCCAGU-3' (SEQ ID NO: 10). In yet another
embodiment,the antisense oligonucleotide has a sequence of
5'-ACUCCAAGUCCAGU-3' (SEQ ID NO: 11). In still
another embodiment, the antisense oligonucleotide has a
sequence of 5''UGACUCCAAGUCCAGU-3' (SEQ ID NO:
12) or 5-CUGACUCCAAGUCCAG-3' (SEQ ID NO:13). In
certain embodiments, the antisense oligonucleotide has a
sequence of 5'-TGACTCCAAGTCCAG-3' (SEQ ID NO:
21).
Exemplary antisense oligonucleotides for inhibiting miR-
378* expression or activity include, but are not limited to,
5'-ACACAGGACCUGGAGUCAGGAG-3' (SEQ ID NO:
14); 5'-GUCAGGAG-3' (SEQ ID NO:15); 5'-GAGUCAG-
GAG-3' (SEQ ID NO: 16); 5''UGGAGUCAGGAG-3' (SEQ
ID NO:17); 5'-CCUGGAGUCAGGAG-3' (SEQ ID NO:18);
5'-GACCUGGAGUCAGGAG-3' (SEQ ID NO: 19);
5'-GGACCUGGAGUCAGGA-3' (SEQ ID NO: 20), and
5'-GACCTGGAGTCAGGA-3'(SEQ ID NO:22).
Antisense oligonucleotides can comprise a sequencethatis
at least partially complementary to a mature or minor(i.e.
star) miR-378 sequence,e.g. at least about 75%, 80%, 85%,
90%, 95%, 96%, 97%, 98%, or 99% complementary to a
mature or minor (1c. star) miR-378 sequence. In some
embodiments, the antisense oligonucleotide can be substan-
tially complementary to a mature or minor miR-378
sequence,thatis at least about 90%, 95%, 96%, 97%, 98%,or
99% complementary to a target polynucleotide sequence. In
one embodiment, the antisense oligonucleotide comprises a
sequence that is 100% complementary to a mature or minor
miR-378 sequence. In certain embodiments, the antisense
oligonucleotideis at least partially complementary to SEQ ID
NO:1. In other embodiments,the antisense oligonucleotide is
at least partially complementary to SEQ ID NO:2.
In some embodiments, the antisense oligonucleotides are
antagomirs. “Antagomirs” are single-stranded, chemically-
modified ribonucleotides that are at least partially comple-
mentary to a miR-378 or miR-378* sequence. Antagomirs
may comprise one or more modified nucleotides, such as
2'-O-methyl-sugar modifications. In some embodiments,
antagomirs comprise only modified nucleotides. Antagomirs
can also comprise one or more phosphorothioate linkages
US 8,716,258 B2
13
resulting in a partial or full phosphorothioate backbone. To
facilitate in vivo delivery andstability, the antagomir can be
linked to a cholesterol or other moiety at its 3' end. Antago-
mirs suitable for inhibiting miR-378 or miR-378* can be
about 15 to about 50 nucleotides in length, more preferably
about 18 to about 30 nucleotides in length, and most prefer-
ably about 20 to about 25 nucleotides in length. The antago-
mirs can beat least about 75%, 80%, 85%, 90%, 95%, 96%,
97%, 98%, or 99% complementary to a mature or minor
miR-378 sequence. In some embodiments, the antagomir
may be substantially complementary to a mature or minor
miR-378 sequence, that is at least about 95%, 96%, 97%,
98%, or 99% complementary to a target polynucleotide
sequence. In other embodiments, the antagomirs are 100%
complementary to a mature or minor miR-378 sequence.
Theinhibitory nucleotide molecules described herein pref-
erably target the mature sequence of miR-378 (SEQ ID NO:
1). In one embodiment, the inhibitory nucleotide molecules
described herein target the minor(i.e. miR-378*) sequence of
miR-378 (SEQ ID NO:2). In some embodiments, inhibitors
of miR-378 and/or miR-378* are antagomirs comprising a
sequence that is perfectly complementary to the mature or
minor miR-378 sequence. In one embodiment,an inhibitor of
miR-378 is an antagomir having a sequencethatis partially or
perfectly complementary to 5'-ACUGGACUUGGAGUCA-
GAAGG-3' (SEQ ID NO: 1). In another embodiment, an
inhibitor ofmiR-378* is an antagomir having a sequencethat
is partially or perfectly complementary to 5'-CUC-
CUGACUCCAGGUCCUGUGU-3' (SEQ ID NO: 2). In
some embodiments, inhibitors ofmiR-378 and/or miR-378*
are chemically-modified antisense oligonucleotides. In one
embodiment, an inhibitor ofmiR-378 is a chemically-modi-
fied antisense oligonucleotide comprising a sequence sub-
stantially complementary to 5'-ACUGGACUUGGAGUCA-
GAAGG-3' (SEQ ID NO: 1). In another embodiment, an
inhibitor of miR-378* is a chemically-modified antisense
oligonucleotide comprising a sequence substantially comple-
mentary to 5'-CUCCUGACUCCAGGUCCUGUGU-3'
(SEQ ID NO:2). As used herein “substantially complemen-
tary” refers to a sequence that is at least about 95%, 96%,
97%, 98%, 99%, or 100% complementary to a target poly-
nucleotide sequence (e.g. mature, minor, or precursor
miRNAsequence).
Antisense oligonucleotides or antagomirs may comprise a
sequencethat is substantially complementary to a precursor
miRNAsequence (pre-miRNA)or primary miRNA sequence
(pri-miRNA) for miR-378. In some embodiments,the anti-
sense oligonucleotide comprises a sequence that is substan-
tially complementary to a sequence located outside the stem-
loop region of the pre-miR-378 sequence. In one
embodiment, an inhibitor ofmiR-378 function is an antisense
oligonucleotide having a sequence that is substantially
complementary to a pre-miR-378 sequence (SEQ ID NO:3).
An agonist of miR-378 and/or miR-378* expression or
activity canbea polynucleotide comprising a miR-378 and/or
miR-378* sequence. For instance, in one embodiment the
miR-378 agonist is a polynucleotide comprising a mature
miR-378 sequence (SEQ ID NO:1). In another embodiment,
the miR-378* agonist is a polynucleotide comprising a minor
(i.e. star) miR-378 sequence (SEQ ID NO:2). In still another
embodiment, the miR-378 agonist can be a polynucleotide
comprising the pri-miRNA sequence for miR-378. In yet
another embodiment, the miR-378 and/or miR-378* agonist
can be a polynucleotide comprising the pre-miRNA sequence
for miR-378 (e.g., SEQ ID NO:3). The polynucleotide com-
prising a miR-378 and/or miR-378* sequence can be from
about 18 to about 2000 nucleotides in length, about 70 to
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about 200 nucleotides in length, about 20 to about 50 nucle-
otides in length, or about 18 to about 25 nucleotides in length.
The polynucleotide comprising the mature miR-378, minor
miR-378 (i.e. miR-378*), pre-miR-378, or pri-miR-378
sequence can be single stranded or double-stranded. The
polynucleotides can contain one or more chemical modifica-
tions, such as locked nucleic acids, peptide nucleic acids,
sugar modifications, such as 2'-O-alkyl (e.g. 2'-O-methyl,
2'-O-methoxyethyl), 2'-fluoro, and 4' thio modifications, and
backbone modifications, such as one or more phosphorothio-
ate, morpholino, or phosphonocarboxylate linkages. In one
embodiment, the polynucleotide comprising a miR-378
sequence(e.g., mature miR-378, miR-378*, pre-miR-378, or
pri-miR-378) is conjugated to a steroid, such as cholesterol, a
vitamin, a fatty acid, a carbohydrate or glycoside, a peptide,
or another small molecule ligand.
Anyofthe inhibitors or agonists of miR-378 and/or miR-
378* described herein can be deliveredto thetargetcell (e.g.
heart, adipose, or skeletal muscle cell) by deliveringto the cell
an expression vector encoding the miR-378 inhibitors or ago-
nists. A “vector”is a composition ofmatterwhich can be used
to deliver a nucleic acid of interest to the interior of a cell.
Numerous vectors are known in the art including, but not
limited to,linear polynucleotides, polynucleotides associated
with ionic or amphiphilic compounds, plasmids, and viruses.
Thus, the term “vector” includes an autonomouslyreplicating
plasmid or a virus. Examplesofviral vectors include, but are
not limited to, adenoviral vectors, adeno-associated virus
vectors, retroviral vectors, and the like. An expression con-
struct can be replicated in a living cell, or it can be made
synthetically. For purposes of this application, the terms
“expression construct,” “expression vector,” and “vector,” are
used interchangeably to demonstrate the application of the
invention in a general, illustrative sense, and are not intended
to limit the invention.
In one embodiment, an expression vector for expressing an
inhibitor ofmiR-378 and/or miR-378* comprises a promoter
operably linked to a polynucleotide encoding an antisense
oligonucleotide, wherein the sequence of the expressed anti-
sense oligonucleotideis partially or perfectly complementary
to a mature or minor sequence ofmiR-378 (e.g., SEQ ID NO:
1 or SEQ ID NO:2). In another embodiment, an expression
vector for expressing a polynucleotide comprising a miR-378
sequence comprises a promoter operably linked to a poly-
nucleotide comprising a mature miR-378 sequence(e.g.,
SEQ ID NO: 1), a minor miR-378 sequence (e.g., SEQ ID
NO:2), a pre-miR-378 sequence (e.g., SEQ ID NO:3), or a
pri-miR-378 sequence. The phrase “operably linked” or
“under transcriptional control” as used herein meansthat the
promoteris in the correct location and orientation in relation
to a polynucleotideto controlthe initiation oftranscription by
RNA polymerase and expression of the polynucleotide.
As used herein, a “promoter” refers to a DNA sequence
recognized by the synthetic machinery of the cell, or intro-
duced synthetic machinery, required to initiate the specific
transcription of a gene. Suitable promoters include, but are
not limited to RNA polI, pol I], pol HI, and viral promoters
(e.g. human cytomegalovirus (CMV) immediate early gene
promoter, the SV40 early promoter, and the Rous sarcoma
virus long terminalrepeat). In one embodiment, the promoter
is a tissue-specific promoter. Ofparticular interest are muscle
specific promoters, and more particularly, cardiac specific
promoters. These include the myosin light chain-2 promoter
(Franzet al. (1994) Cardioscience, Vol. 5(4):235-43; Kelly et
al. (1995) J. Cell Biol., Vol. 129(2):383-396), the alpha actin
promoter (Moss et al. (1996) Biol. Chem., Vol. 271(49):
31688-31694), the troponin 1 promoter (Bhaysaretal. (1996)
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Genomics, Vol. 35(1):11-23); the Na+/Ca2+ exchangerpro-
moter (Barnes et al. (1997) J. Biol. Chem., Vol. 272(17):
11510-11517), the dystrophin promoter (Kimuraet al. (1997)
Dev. Growth Differ., Vol. 39(3):257-265), the alpha7 integrin
promoter (Ziober and Kramer (1996) J. Bio. Chem., Vol.
271(37):22915-22), the brain natriuretic peptide promoter
(LaPointe et al. (1996) Hypertension, Vol. 27(3 Pt 2):715-22)
and the alpha B-crystallin/small heat shock protein promoter
(Gopal-Srivastava (1995) J. Mol. Cell. Biol., Vol. 15(12):
7081-7090), alpha myosin heavy chain promoter (Yamauchi-
Takihara et al. (1989) Proc. Natl. Acad. Sci. USA, Vol. 86(10):
3504-3508) and the ANF promoter (LaPointe et al. (1988) /.
Biol. Chem., Vol. 263(19):9075-9078). In one embodiment,
the tissue-specific promoter is an adipocyte-specific pro-
moter, such as an adipocyte protein 2 (ap2)/fatty acid binding
protein 4 (FABP4) promoter or a PPARy promoter.
In certain embodiments, the promoter operably linked to a
polynucleotide encoding a miR-378 and/or miR-378* inhibi-
tor or a polynucleotide encoding a miR-378 sequence can be
an inducible promoter. Inducible promoters are knownin the
art and include, but are not limitedto, tetracycline promoter,
metallothionein IIA promoter, heat shock promoter, steroid/
thyroid hormone/retinoic acid response elements, the aden-
ovirus late promoter, and the inducible mouse mammary
tumorvirus LTR.
Methods of delivering expression constructs and nucleic
acids to cells are known in the art and can include, for
example, calcium phosphate co-precipitation, electropora-
tion, microinjection, DEAE-dextran, lipofection, transfec-
tion employing polyaminetransfection reagents, cell sonica-
tion, gene bombardment using high velocity
microprojectiles, and receptor-mediated transfection.
The present invention also includes methods for scaveng-
ing or clearing miR-378 and/or miR-378* inhibitors follow-
ing treatment. The method may comprise overexpressing
binding sites for the miR-378 and/or miR-378* inhibitors in
cardiac or skeletal muscle tissue. The binding site regions
preferably contain a sequenceofthe seed region for miR-378
and/or miR-378*. The seed region is the 5' portion of a
miRNA spanning bases 2-8, which is important for target
recognition. In some embodiments, the binding site may con-
tain a sequence from the 3'UTR of one or more targets of
miR-378 and/or miR-378*, such as SuFu, Fus-1, glutamine:
fructose-6-phosphate amidotransferase-2 (GFPT2), and
MED 13.
The present invention also includes pharmaceutical com-
positions comprising an inhibitor or agonist ofmiR-378 and/
or miR-378*. Where clinical applications are contemplated,
pharmaceutical compositions will be prepared in a form
appropriate for the intended application. Generally, this will
entail preparing compositions that are essentially free of
pyrogens, as well as other impurities that could be harmful to
humansor animals.
In one embodiment, the pharmaceutical composition com-
prises an effective dose of a miR-378 and/or miR-378*
inhibitor and a pharmaceutically acceptable carrier. For
instance, the pharmaceutical composition comprises and
effective dose of a modified antisense oligonucleotide target-
ing miR-378 and/or miR-378* as described herein. In some
embodiments, the pharmaceutical composition comprises a
modified antisense oligonucleotide having a sequence
selected from the group consisting of SEQ ID NO:7, SEQ ID
NO: 8, SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO: 11, SEQ
ID NO:12, SEQ ID NO: 13, SEQID NO: 14, SEQID NO:15,
SEQ ID NO:16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID
NO: 19, SEQ ID NO:20, SEQ ID NO:21, and SEQ ID NO:
22. In another embodiment, the pharmaceutical composition
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comprises an effective dose of a miR-378 and/or miR-378*
agonist as described herein and a pharmaceutically accept-
able carrier. An “effective dose” is an amount sufficient to
effect a beneficial or desired clinical result. An effective dose
of an miRNA inhibitor or miRNA agonist of the invention
may be from about 1 mg/kg to about 100 mg/kg, about 2.5
mg/kg to about 50 mg/kg, or about 5 mg/kg to about 25
mg/kg. The precise determination of what would be consid-
ered an effective dose may be based on factors individual to
each patient, including their size, age, type of disorder(e.g.
myocardial infarction, heart failure, cardiac hypertrophy,
metabolic disorder), and nature of inhibitor or agonist(e.g.
antagomir, expression construct, antisense oligonucleotide,
polynucleotide duplex, etc). Therefore, dosages can be
readily ascertained by those of ordinary skill in the art from
this disclosure and the knowledgein theart.
Colloidal dispersion systems, such as macromolecule
complexes, nanocapsules, microspheres, beads, and lipid-
based systems including oil-in-water emulsions, micelles,
mixed micelles, and liposomes, may be used as delivery
vehicles for the oligonucleotide inhibitors ofmiR-378 and/or
miR-378* function, polynucleotides encoding miR-378 and/
or miR-378* agonists, or constructs expressing particular
miRNA inhibitors or agonists. Commercially available fat
emulsionsthat are suitable for delivering the nucleic acids of
the invention to cardiac and skeletal muscle tissues include
Intralipid®, Liposyn®, Liposyn® IJ, Liposyn® II, Nutril-
ipid, and other similar lipid emulsions. A preferred colloidal
system for use asa delivery vehicle in vivois a liposome(1.e.,
an artificial membrane vesicle). The preparation and use of
such systems is well known in the art. Exemplary formula-
tions are also disclosed in U.S. Pat. No. 5,981,505; U.S. Pat.
No. 6,217,900; U.S. Pat. No. 6,383,512; U.S. Pat. No. 5,783,
565; U.S. Pat. No. 7,202,227; U.S. Pat. No. 6,379,965; U.S.
Pat. No. 6,127,170; U.S. Pat. No. 5,837,533; U.S. Pat. No.
6,747,014; andWO03/093449, which are herein incorporated
by reference in their entireties.
One will generally desire to employ appropriate salts and
buffers to render delivery vehicles stable and allow for uptake
by target cells. Aqueous compositions of the present inven-
tion comprise an effective amount of the delivery vehicle
comprising the inhibitor polynucleotides (e.g. liposomes or
other complexes or expression vectors) dissolved or dis-
persed in a pharmaceutically acceptable carrier or aqueous
medium. The phrases “pharmaceutically acceptable” or
“pharmacologically acceptable” refers to molecular entities
and compositions that do not produce adverse, allergic, or
other untoward reactions when administered to an animal or
a human.As used herein, “pharmaceutically acceptable car-
rier” includes solvents, buffers, solutions, dispersion media,
coatings, antibacterial and antifungal agents, isotonic and
absorption delaying agents and the like acceptable for use in
formulating pharmaceuticals, such as pharmaceuticals suit-
able for administration to humans. The use ofsuch media and
agents for pharmaceutically active substances is well known
in the art. Except insofar as any conventional media or agent
is incompatible with the active ingredients of the present
invention, its use in therapeutic compositions is contem-
plated. Supplementary active ingredients also can be incor-
porated into the compositions, provided they do not inactivate
the vectors or polynucleotides of the compositions.
The active compositions of the present invention may
include classic pharmaceutical preparations. Administration
ofthese compositions accordingto the present invention may
be via any common route so long as the target tissue is
available via that route. This includesoral, nasal, or buccal.
Alternatively, administration may be by intradermal, subcu-
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taneous, intramuscular, intraperitoneal or intravenousinjec-
tion, or by direct injection into cardiac tissue. Pharmaceutical
compositions comprising miRNA inhibitors, miRNA ago-
nists or expression constructs comprising miRNAinhibitors
or agonists may also be administered by catheter systems or
systemsthat isolate coronary circulation for delivering thera-
peutic agentsto the heart. Various catheter systemsfor deliv-
ering therapeutic agents to the heart and coronary vasculature
are knownin the art. Some non-limiting examples ofcatheter-
based delivery methods or coronary isolation methodssuit-
able for use in the present invention are disclosed in US.Pat.
No. 6,416,510; U.S. Pat. No. 6,716,196; U.S. Pat. No. 6,953,
466, WO 2005/082440, WO 2006/089340, U.S. Patent Pub-
lication No. 2007/0203445, U.S. Patent Publication No.
2006/0148742, and U.S. Patent Publication No. 2007/
0060907, which are all herein incorporated by reference in
their entireties. Such compositions would normally be
administered as pharmaceutically acceptable compositions
as described herein.
The active compounds mayalso be administered parenter-
ally or intraperitoneally. By way ofillustration, solutions of
the active compounds as free base or pharmacologically
acceptable salts can be prepared in water suitably mixed with
a surfactant, such as hydroxypropylcellulose. Dispersions
can also be preparedin glycerol, liquid polyethylene glycols,
and mixtures thereofandin oils. Under ordinary conditions of
storage and use, these preparations generally contain a pre-
servative to prevent the growth of microorganisms.
The pharmaceutical forms suitable for injectable use or
catheter delivery include, for example, sterile aqueous solu-
tionsor dispersions andsterile powders for the extemporane-
ous preparation ofsterile injectable solutions or dispersions.
Generally, these preparationsare sterile and fluid to the extent
that easy injectability exists. Preparations should be stable
under the conditions of manufacture and storage and should
be preserved against the contaminating action ofmicroorgan-
isms, such as bacteria and fungi. Appropriate solvents or
dispersion media may contain, for example, water, ethanol,
polyol (for example, glycerol, propylene glycol, and liquid
polyethylene glycol, and the like), suitable mixtures thereof,
and vegetable oils. The properfluidity can be maintained, for
example, by the use of a coating, such as lecithin, by the
maintenance of the required particle size in the case of dis-
persion and by the use of surfactants. The prevention of the
action of microorganisms can be brought about by various
antibacterial an antifungal agents, for example, parabens,
chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
In manycases,it will be preferable to include isotonic agents,
for example, sugars or sodium chloride. Prolonged absorp-
tion of the injectable compositions can be brought about by
the use in the compositions ofagents delaying absorption, for
example, aluminum monostearate and gelatin.
Sterile injectable solutions may be prepared by incorporat-
ing the active compounds in an appropriate amount into a
solvent along with any other ingredients (for example as
enumerated above) as desired, followed byfiltered steriliza-
tion. Generally, dispersions are prepared by incorporating the
various sterilized active ingredients into a sterile vehicle
which containsthe basic dispersion medium andthe desired
other ingredients, e.g., as enumerated above. In the case of
sterile powders for the preparation ofsterile injectable solu-
tions, the preferred methods of preparation include vacuum-
drying and freeze-drying techniques which yield a powder of
the active ingredient(s) plus any additional desired ingredient
from a previously sterile-filtered solution thereof.
The compositions of the present invention generally may
be formulated in a neutral or salt form. Pharmaceutically-
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acceptable salts include, for example, acid addition salts
(formed with the free amino groupsofthe protein) derived
from inorganic acids (e.g., hydrochloric or phosphoricacids),
or from organic acids (e.g., acetic, oxalic, tartaric, mandelic,
and the like). Salts formed with the free carboxyl groups of
the protein can also be derived from inorganic bases(e.g.,
sodium, potassium, ammonium,calcium, or ferric hydrox-
ides) or from organic bases(e.g., isopropylamine, trimethy-
lamine,histidine, procaine andthelike).
Upon formulation, solutionsare preferably administered in
a manner compatible with the dosage formulation and in such
amountas is therapeutically effective. The formulations may
easily be administered in a variety of dosage forms such as
injectable solutions, drug release capsules and the like. For
parenteral administration in an aqueous solution, for
example, the solution generally is suitably buffered and the
liquid diluentfirst rendered isotonic for example with suffi-
cient saline or glucose. Such aqueoussolutions may be used,
for example, for intravenous, intramuscular, subcutaneous
and intraperitoneal administration. Preferably, sterile aque-
ous media are employedas is knownto those ofskill in theart,
particularly in light of the present disclosure. By way of
illustration, a single dose may be dissolved in 1 ml of isotonic
NaC]solution and either added to 1000 ml ofhypodermocly-
sis fluid or injected at the proposedsite of infusion, (see for
example, “Remington’s Pharmaceutical Sciences” 15th Edi-
tion, pages 1035-1038 and 1570-1580). Some variation in
dosage will necessarily occur depending on the condition of
the subject being treated. The person responsible for admin-
istration will, in any event, determine the appropriate dose for
the individual subject. Moreover, for human administration,
preparations should meetsterility, pyrogenicity, general
safety and purity standards as required by FDA Office of
Biologics standards.
In certain embodimentsofthe invention, the pharmaceuti-
cal compositionsofthe invention are packaged with or stored
within a device for administration. Devices for injectable
formulations include, but are not limited to, injection ports,
autoinjectors, injection pumps, and injection pens. Devices
for aerosolized or powder formulations include, but are not
limited to, inhalers, insufflators, aspirators, andthe like. Thus,
the present invention includes administration devices com-
prising a pharmaceutical composition of the invention for
treating or preventing one or more ofthe disorders described
herein.
This invention is further illustrated by the following addi-
tional examples that should not be construed as limiting.
Thoseofskill in the art should, in lightofthe present disclo-
sure, appreciate that many changes canbe madeto the specific
embodiments which are disclosed andstill obtain a like or
similar result without departing from the spirit and scope of
the invention.
EXAMPLES
Example 1
miR-378/miR-378* is Highly Expressed in
Mitochondrial-Rich Tissues
Expression profiling of miRNAsin the failing heart has
been described previously using mouse modelsofheart dis-
ease (van Roojj et al. (2006) Proc. Natl. Acad. Sci. USA,Vol.
103:18255-18260). MicroRNA microarray analysis carried
out in tissue obtained from hearts with hypertrophy induced
by pressure overload, calcineurin overexpression or isoprot-
erenol administration revealed that miR-378 (GeneID:
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723889) is one ofthe most robustly regulated miRNAs under
these conditions. MiR-378 is also down-regulated in myocar-
dial infarction (van Rooij et al. (2008) Proc. Natl. Acad. Sci.
USA, Vol. 105:13027-13032), providing further evidence
that miR-378 is an important determinant of the cardiac
stress-response program. MiR-378is located on murine chro-
mosome18, within thefirst intron of the Peroxisomeprolif-
erator-activated receptor gamma coactivator 1-beta
(PPARGC1, GeneID: 170826) gene (FIG. 1A).
To examine the expression profile of miR-378 and miR-
378*, quantitative real time PCR analysis of various tissues
isolated from mice was performed. MiR-378 and miR-378*
were found to be highly expressedin heart, skeletal muscle,
and brown adiposetissue (FIG. 1B).In heart tissue, miR-378
was more highly expressed in cardiomyocytes than in cardiac
fibroblasts (FIG. 1C). The expression pattern of miR-378/
miR-378* andtheir host gene, PPARGC1£ (PGC-1B), were
overlapping (FIG. 1B), suggesting that miR-378/miR-378*
and PPARGC16 are co-transcribed. Consistent with this
hypothesis, a reduction in the expression level of miR-378
wasobservedin cell culture upon treatment with stearic acid,
a knownrepressor ofPPARGC16 expression (FIG. 1D). The
expression of both miR-378 and its host gene, PPARGC1B
(PGC-16), is increased during adipogenesis (FIG. 1F). It has
been shown that acute elevation of plasma levels of stearic
acid, as well as other short chain fatty acids down-regulates
PPARGC1la, PPARGC1 and PPARa expression (Staiger et
al. (2005) Diabetologia, Vol. 48:2115-2118). The observation
that the transcription of both miR-378 and the host gene
PPARGC1£ follow parallel regulatory patterns strongly sug-
gests that the two genes are co-regulated. PPARGC16 is
knownto play a role in the regulation of fatty acid oxidation,
glucose utilization, and mitochondrial biogenesis (Handschin
and Spiegelman (2006) Endocr. Rev., Vol. 27:728-735; Lel-
liott et al. (2006) PLoSBiol., Vol. 4:2042-2056; Luptak etal.
(2005) Circulation, Vol. 112:2339-2346; Sonodaet al. (2007)
Proc. Natl. Acad. Sci. USA, Vol. 104:5223-5228; andVianna
et al. (2006) Cell Metab., Vol. 4:453-464). It is likely that
miR-378/miR-378* play a role in these same processes as
intronic miRNAsoften participate in the same network of
gene programsastheir host gene.
Example 2
MiR-378 Regulates the Stress-Induced Cardiac
Hypertrophic Response
To further elucidate the role ofmiR-378 in cardiac disease,
miR-378 expression wasassessedin heart tissue after induc-
tion of cardiac hypertrophy by thoracic aortic banding (TAB)
in wild-type mice. Specifically, the aorta was sutured to the
diameter ofa 27-gauge needle, inducing pressure overload on
the heart, thus mimicking hypertension. Control animals
were subject to a sham surgery in which the aorta was not
altered. MicroRNA microarray analysis and real-time PCR of
cardiac tissue isolated 21 days following the TAB procedure
revealed that miR-378 is down-regulated in responseto pres-
sure overload (FIG. 2A).
To examinethe effect ofoverexpression ofmiR-378 during
heart disease, transgenic mice were generated that overex-
press miR-378/miR-378* underthe control ofthe cardiomyo-
cyte-specific a-myosin heavy chain (a-MHC)promoter.Fol-
lowing TAB, these transgenic animals displayed an
exacerbated cardiac hypertrophic response comparedto wild-
type mice (FIG. 2B). These findings show that the forced
expression of miR-378 during heart disease is deleterious to
the heart and the decrease of miR-378 in wild-type mice
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following TAB is suggestive of a protective response of the
heart against the appliedstress.
MiR-378 is likely to play a role in the process of cardiac
metabolism, specifically the hypertrophic metabolic shift
(Luptak et al. (2005) Circulation, Vol. 112:2339-2346). We
suggest that miR-378 augments the cardiac metabolic shift
and thus participates in the cardiac hypertrophic response
under stress. Inhibition of miR-378 expression or activity
may provide a therapeutic benefit in patients with cardiovas-
cular diseases.
Example 3
Overexpression of miR-378 in Skeletal Muscle
Results in Increased Body Weight and Epididymal
Fat Mass
To examinethe effect of the overexpression ofmiR-378 in
the skeletal muscle, transgenic mice were generatedthat over-
express miR-378/miR-378* under the control of the muscle
creatine kinase (MCK) promoter. Preliminary investigation
of the MCK-miR-378 transgenic animals revealed that miR-
378 modulates glucose andfatty acid utilization.In particular,
older age (10 months of age) transgenic animals weighed
significantly more than wild-type littermates (FIG. 3). The
difference in body weight resulted from increased weight of
epididymal white fat pads in mutant animals as compared to
wild-type animals (FIG. 3). Histological analysis ofthe white
fat tissue showed adipocyte hypertrophy in miR-378-overex-
pressing mice (FIG. 3). The increased accumulation oftrig-
lycerides in the adipocytes of MCK-miR-378 transgenic ani-
mals is likely the consequenceofincreased insulin resistance
and global defects in glucose utilization.
In another series of experiments, miR-378 was overex-
pressed in 3T3-L1 cells, which were subsequently induced to
differentiate into adipocytes. As demonstrated by Oil red O
staining, increased lipid accumulation was observed in cells
overexpressing miR-378 providing further evidence of the
involvement of miR-378 in the regulation of metabolic pro-
cesses (FIG.4).
Microarray analysis of various tissues isolated from obese
mice (ob/ob) and diabetes mice (db/db) revealed that miR-
378 is strongly down-regulated (data not shown). Ob/ob mice
have a mutation in the gene encoding leptin, which causes
them to be unable to producethe leptin hormone and properly
regulate appetite. Db/db mice have a mutation in the gene
encoding the leptin receptor that causes an abnormalsplicing
ofthe transcript leadingto truncation ofthe cellular domain of
the receptor. The mutant leptin receptor lacks signal trans-
duction function. We suggest that the regulation of miR-378
in these animal models of obesity and diabetes represents a
protective mechanism against the metabolic disorders
inducedbythe disruption ofleptin signaling. Thus, miR-378
may represent an effective therapeutic target for various
metabolic disorders.
Example 4
Transgenic Mice Overexpressing miR-378 in
Skeletal Muscle Exhibit Reduced Glucose Tolerance
To further examine the role of miR-378 in regulation of
glucoseutilization, transgenic mice overexpressing miR-378
in skeletal muscle (MCK-miR-378 Tg; see Example 3) were
subject to a glucosetolerance test (GTT)to detect any poten-
tial deficits in clearance of glucose from the blood. Mice
fasted for 16 hours and were subsequently injected intraperi-
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toneally (-p.) with 1.5 g/kg of glucose. Blood samples were
obtained before glucose injection and 15, 30, 60, and 120
minutes following glucose injection. As shown in FIG. 5,
blood glucose levels were elevated in miR-378 transgenic
mice and clearance of glucose from the blood was delayed as
compared to wild-type mice. These results show that overex-
pression ofmiR-378 in skeletal muscle leads to reduced glu-
cose tolerance possibly due to increased insulin resistance in
these animals.
To determine whetherthe effect on glucose tolerance was
due specifically to miR-378 overexpression, MCK-miR-378
transgenic animals were injected via the tail vein with 10
mg/kg of antimiR-378 for three consecutive days. AntimiR-
378 had a sequence that was complementary to nucleotides
2-16 of the mature miR-378 sequence (5'-TGACTC-
CAAGTCCAG-3' (SEQ ID NO:21)) and contained a com-
bination of locked nucleic acids and deoxyribonucleotides (8
LNAsand 7 DNAs). AntimiR-378 contained a full phospho-
rothioate backbone. Following the last injection of antimiR-
378, mice were fasted for 16 hours. Glucose (1.5 g/kg) was
injected i.p. and blood samples were obtained before andat
varioustime points following glucose injection. AntimiR-378
effectively reduced expression ofmiR-378 in transgenic mice
to levels below those observed in saline-injected wild-type
mice (FIG. 6). AntimiR-378 treatment of transgenic animals
improved glucose clearance suchthat these animals exhibited
a similar response as wild-type animals to the glucosetoler-
ance test. These results suggest that the aberrant glucose
utilization in miR-378 transgenic mice was due to overex-
pression ofmiR-378 andthat normal metabolic processes can
be restored by reducing the expression of miR-378.
To test whether antimiR-378 could restore normal glucose
utilization in a mouse modeloftype 2 diabetes, obese (ob/ob)
mice were injected intravenously with 10 mg/kg of antimiR-
378 for three consecutive days. Following the last antimiR-
378 injection, mice were fasted for 16 hours andinjected i-p.
with 1.5 g/kg glucose. Blood samples were obtained at vari-
ous intervals after injection to assess blood glucose level. As
shown in FIG.7, ob/ob mice treated with antimiR-378 exhib-
ited improved glucose clearance as compared to untreated
animals. These findings demonstrate that inhibition of miR-
378 expression is able to improve glucoseutilization in ani-
mals with chronic disruption of leptin signaling. Therefore,
miR-378 inhibitors provide a novel therapeutic approach for
treating metabolic disorders, such as diabetes and obesity.
Example 5
Generation of miR-378 Knockout Mice
To determine the function ofmiR-378/miR-378*in vivo, a
mouseline with a genetic deletion ofmiR-378/miR-378* was
generated. Using a targeting vector and homologous recom-
bination (FIG. 8A), miR-378/miR-378* was targeted and
germline transmission of the genetic deletion was confirmed
using Southern blot analysis (FIG. 8B). Northern blot analy-
sis confirmed loss of miR-378/miR-378* expression in all
tissues examined in the miR-378 global mutant (FIG. 8C).
Real time PCR analysis using a Taqman probe for
PPARGC1b and Western Blot analysis for PPARGC1B
(PGC-1B) showed that PPARGC1B (PGC-1B) expression is
not altered in the miR-378 knockout animal (FIG. 8D).
To determine the effect of miR-378 loss of function on
cardiac remodeling, thoracic aortic banding (TAB) wasper-
formed on wild-type and miR-378 global knockout mice.
Echocardiography was performed to determine fractional
shortening, a measure of cardiac contractility and function,
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ejection fraction, systolic diameter, and diastolic-systolic
diameter (DD-SD) on day 21 post TAB. Hearts were har-
vested one day after echocardiography. Histology was per-
formed to determine cellular morphology. Expression of car-
diac remodeling/stress genes, such as ANF, BNP, Myh7,
Myhé,and collagen, was measuredby real-time quantitative
PCR.
Theresults ofthis series ofexperiments show that miR-378
knockout animals were protected from TAB-induced cardiac
remodeling. Hearts from knockout animals exhibited reduced
myocyte hypertrophy and cardiac fibrosis measured by his-
tologic analysis when compared to wild-type mice (FIG.9).
Sunilarly, the miR-378 knockouts were protected from a
decrease in cardiac contractility and function as measured by
echocardiography (FIG. 10A-D). The miR-378 knockout ani-
mals also exhibited attenuation of remodeling/stress gene
up-regulation (FIG. 11A-C). These results demonstrate that
miR-378 is a positive regulator of cardiac hypertrophy/re-
modeling and inhibiting miR-378 expression and activity
represents a novel therapeutic approach for reducing patho-
logical remodeling in responseto cardiac stressors.
The miR-378 knockout mice are also crossed to animals
overexpressing the pro-hypertrophic phosphatase cal-
cineurin, which induces a form ofhypertrophic cardiomyopa-
thy. In addition, the cardiac hypertrophic agonist isoproter-
enol orsaline (control) is administered to miR-378 knockout
mice to determine the effect of loss of miR-378 in cardiac
remodeling. MiR-378 knockout animals are expected to be
protected from isoproterenol and calcineurin-induced cardiac
remodeling as well.
Example 6
MiR-378 Knockout Mice are More Resistant to
Weight Gain Induced by High Fat Diet
Inhibition of miR-378 using an antisense oligonucleotide
produced an improvement in glucose utilization in obese
(ob/ob) mice, a model oftype 2 diabetes (see Example 4). To
further explore the role of miR-378/miR-378* in regulating
metabolism, miR-378 knockout mice (see Example 5) were
crossed with obese mice and glucoseutilization wasassessed.
Mice werefasted for 16 hours and injected i-p. with 1.5 g/kg
glucose. Blood samples were obtained at various intervals
after injection to assess blood glucose level. As shown in FIG.
12, the offspring of the miR-378 knockout and ob/ob cross
(ob/ob KO) exhibit an improved glucose tolerance as com-
pared to obese (ob/ob) animals.
To determine whether miR-378/miR-378* plays a role in
the development of other forms of obesity, such as that
inducedby a high-fat diet, miR-378/miR-378* knockout ani-
mals and wild-type littermates were put on a high fat diet
consisting of 45% kcal fat. The knockout animals gained
significantly less body weight than their wild-type counter-
parts after more than four weeks on the high fat diet (FIG.
13A). In addition, after five weeks on a high fat diet, miR-
378/miR-378* knockout animals exhibited enhanced glucose
tolerance as compared to wild-type littermates (FIG. 13B).
Interestingly, miR-378/miR-378* knockout mice had
reduced fat pads and hepatic lipid accumulation after six
weeks on a high fat diet as compared to wild-type animals
(FIGS. 14-16).
Transgenic mice overexpressing miR-378/miR-378* in
heart tissue underthe control ofan alpha-MHCpromoter(see
Example 2) had increased body weight as comparedto wild-
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type animals,and also exhibited a greater percentage change
in body weight than wild-type animals in responseto a high
fat diet (FIG. 17).
Western blot analysis ofbrown adiposetissue isolated from
wild-type and miR-378/miR-378* knockout animals follow-
ing six hours of fasting revealed that AMP-activated protein
kinase (AMPK)signaling is enhanced in adipose tissue iso-
lated from the knockout mice as shown byanincrease in the
phosphorylated form ofAMPK (FIG. 18A). AMPKis a cen-
tral regulator of lipid and glucose metabolism. Activation of
AMPK promotes insulin-stimulated glucose uptake and
stimulates catabolic processes, such as fatty acid oxidation
and glycolysis. Activation ofAMPKresults in the inhibition
of gluconeogenesis, glycogen, lipid and protein synthesis.
Therefore, the absence of miR-378/miR-378* in the knock-
out animals enhances AMPKactivation thereby promoting
fatty acid oxidation and a reduction in lipid accumulation
(FIG. 18B).
Using the miRandasoftware (available from the Compu-
tational Biology Center at Memorial Sloan-Kettering Cancer
Center) for the identification of miRNA targets, mediator
complex subunit 13 (MED13), also known as thyroid hor-
monereceptor associated protein 1 (THRAP1), was identi-
fied as a predicted target for miR-378. The 3' UTR ofMED13
contains four putative binding sites for miR-378/miR-378*
(FIG. 19A) that are conserved across species (e.g. human,
mouse, rat, dog, orangutan, and horse). Examination of
MED13 expression in mice overexpressing miR-378/miR-
378* in the heart (@MHC Tg) revealed that MED 13 expres-
sion is downregulated relative to wild-type animals, while
MED 13 expression is upregulated in miR-378/miR-378*
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knockout animals (KO), suggesting that MED13is a physi-
ological target ofmiR-378/miR-378*. See FIG. 19B. To fur-
ther test whether MED13is a recognized target for miR-378/
miR-378*, the full length 3'-UTR of the MED13 transcript
wasinserted into a luciferase expression plasmid, which was
transfected into COS1 cells. Increasing amounts of CMV-
driven miR-378/miR-378* resulted in a dose-dependent
decrease in luciferase activity, while comparable amounts of
a control miRNA had noeffect (FIG. 19C). Mutating the
3'UTR sequence of MED 13 also abrogated miR-378/miR-
378*-induced suppression ofluciferase activity (FIG. 19C).
Taken together, the results of this series of experiments
show that miR-378/miR-378* plays a key role in regulating
metabolic processes by influencing AMPK and MED13 sig-
naling. Inhibition of miR-378/miR-378* activity may repre-
sent a viable therapeutic approach for treating metabolic dis-
orders, such as obesity and type II diabetes.
All publications, patents and patent applications discussed
and cited herein are incorporated herein by reference in their
entireties. It is understood that the disclosed invention is not
limited to the particular methodology, protocols and materi-
als described as these can vary. It is also understoodthat the
terminology used herein is for the purposes of describing
particular embodiments only and is not intended to limit the
scope ofthe present invention which will be limited only by
the appended claims.
Those skilled in the art will recognize, or be able to ascer-
tain using no more than routine experimentation, many
equivalents to the specific embodiments of the invention
described herein. Such equivalents are intended to be encom-
passed by the following claims.
 
SEQUENCE LISTING
<160> NUMBER OF SEQ ID NOS: 22
<210>
<211>
<212>
<213>
SEQ ID NO 1
LENGTH: 21
TYPE: RNA
ORGANISM: Homo sapiens
<400> SEQUENCE: 1
acuggacuug gagucagaag g
<210>
<211>
<212>
<213>
SEQ ID NO 2
LENGTH: 22
TYPE: RNA
ORGANISM: Homo sapiens
<400> SEQUENCE: 2
cuccugacuc cagguccugu gu
<210>
<211>
<212>
<213>
SEQ ID NO 3
LENGTH: 66
TYPE: RNA
ORGANISM: Homo sapiens
<400> SEQUENCE: 3
agggcuccug acuccagguc cuguguguua ccuagaaaua gcacuggacu uggagucaga
aggecu
<210> SEQ ID NO 4
<211> LENGTH: 21
<212> TYPE: RNA
21
22
60
66
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<213> ORGANISM: Mus musculus
<400> SEQUENCE: 4
acuggacuug gagucagaag g
<210> SEQ ID NO 5
<211> LENGTH: 22
<212> TYPE: RNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 5
cuccugacuc cagguccugu gu
<210> SEQ ID NO 6
<211> LENGTH: 66
<212> TYPE: RNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 6
agggcuccug acuccagguc cuguguguua ccucgaaaua gcacuggacu uggagucaga
aggecu
<210> SEQ ID NO 7
<211> LENGTH: 21
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: miR-378 inhibitor
<400> SEQUENCE: 7
ecuucugacu ccaaguccag u
<210> SEQ ID NO 8
<211> LENGTH: 8
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: miR-378 inhibitor
<400> SEQUENCE: 8
aguccagu
<210> SEQ ID NO 9
<211> LENGTH: 10
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: miR-378 inhibitor
<400> SEQUENCE: 9
caaguccagu
<210> SEQ ID NO 10
<211> LENGTH: 12
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: miR-378 inhibitor
<400> SEQUENCE: 10
uccaagucca gu
<210> SEQ ID NO 11
<211> LENGTH: 14
<212> TYPE: RNA
21
22
60
66
21
10
12
27
US 8,716,258 B2
-continued
28
 
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: miR-378 inhibitor
<400> SEQUENCE:
acuccaaguc cagu
<210> SEQ ID NO
<211> LENGTH: 16
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: miR-378 inhibitor
<400> SEQUENCE:
11
12
12
ugacuccaag uccagu
<210> SEQ ID NO
<211> LENGTH: 16
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: miR-378 inhibitor
<400> SEQUENCE:
cugacuccaa gucca
<210> SEQ ID NO
<211> LENGTH: 22
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: miR-378* inhibitor
<400> SEQUENCE:
acacaggace uggagucagg ag
<210> SEQ ID NO
<211> LENGTH: 8
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: miR-378* inhibitor
<400> SEQUENCE:
gucaggag
<210> SEQ ID NO
<211> LENGTH: 10
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: miR-378* inhibitor
<400> SEQUENCE:
gagucaggag
<210> SEQ ID NO
<211> LENGTH: 12
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: miR-378* inhibitor
<400> SEQUENCE:
uggagucagg ag
13
13
g
14
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<210>
<211>
<212>
<213>
<220>
<223>
SEQ ID NO 18
LENGTH: 14
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: miR-378* inhibitor
<400> SEQUENCE: 18
ccuggaguca ggag
<210>
<211>
<212>
<213>
<220>
<223>
SEQ ID NO 19
LENGTH: 16
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: miR-378* inhibitor
<400> SEQUENCE: 19
gaccuggagu caggag
<210>
<211>
<212>
<213>
<220>
<223>
SEQ ID NO 20
LENGTH: 16
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: miR-378* inhibitor
<400> SEQUENCE: 20
ggaccuggag ucagga
<210>
<211>
<212>
<213>
<220>
<223>
SEQ ID NO 21
LENGTH: 15
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: miR-378 inhibitor
<400> SEQUENCE: 21
tgactccaag tccag
<210>
<211>
<212>
<213>
<220>
<223>
SEQ ID NO 22
LENGTH: 15
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: miR-378* inhibitor
<400> SEQUENCE: 22
gacctggagt cagga
14
16
16
15
15
 
The invention claimedis:
1. A methodof treating pathologic cardiac hypertrophy,
cardiac remodeling, myocardial infarction, or heart failure in
a subject in need thereof comprising administering to the
subject an inhibitor of miR-378 and/or miR-378*, wherein
the inhibitor is an antisense oligonucleotide.
2. The methodofclaim 1, wherein the expression or activ-
ity ofmiR-378 and/or miR-378* is reduced in the heart cells
of the subject following administration of the inhibitor.
3. The method of claim 1, wherein the antisense oligo-
nucleotide comprises a sequence that is at least partially
complementary to a mature sequence of miR-378 and/or
miR-378*.
4. The method of claim 3, wherein the antisense oligo-
nucleotide comprises a sequencethat is substantially comple-
mentary to SEQ ID NO: 1 or SEQ ID NO:2.
55
60
65
5. The method of claim 3, wherein the antisense oligo-
nucleotide comprises at least one sugar and/or backbone
modification.
6. The method ofclaim 5, wherein the sugar modification is
a locked nucleic acid.
7. The method of claim 5, wherein the backbone modifi-
cation is a phosphorothioate linkage.
8. The method of claim 3, wherein the antisense oligo-
nucleotide is about 7 to about 18 nucleotides in length.
9. The method of claim 3, wherein the antisense oligo-
nucleotide has a sequenceselected from the group consisting
ofSEQ ID NO:7, SEQ ID NO:8, SEQIDNO: 9, SEQID NO:
10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ
ID NO:14, SEQ ID NO: 15, SEQID NO: 16, SEQID NO:17,
SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID
NO: 21, and SEQ ID NO:22.
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10. The method of claim 1, wherein the subject is human.
11. The method ofclaim 1, wherein the inhibitor is admin-
istered to the subject by an intradermal, subcutaneous,intra-
muscular, intraperitoneal or intravenous route of administra-
tion or by direct injection into cardiac tissue.
12. A methodoftreating a metabolic disorder in a subject
in need thereof comprising administering to the subject an
inhibitor ofmiR-378 and/or miR-378*, wherein the inhibitor
is an antisense oligonucleotide, and wherein the expression or
activity ofmiR-378 and/or miR-378*is reduced in the cells of
the subject following administration.
13. The method of claim 12, wherein the metabolic disor-
der is metabolic syndrome, obesity, diabetes mellitus, dia-
betic nephropathy, insulin resistance, atherosclerosis, a lipid
storage disorder, a glycogen storage disease, medium-chain
acyl-coenzyme A dehydrogenase deficiency, or aberrant glu-
cose uptake and/orutilization.
14. The method of claim 13, wherein the lipid storage
disorder is selected from the group consisting of Niemann-
Pick disease, Gaucher’s disease, Farber disease, Fabry dis-
ease, Wolman disease, and cholesteryl ester storage disease.
15. The method of claim 12, wherein the antisense oligo-
nucleotide comprises a sequencethat is substantially comple-
mentary to a mature sequence ofmiR-378 and/or miR-378*.
16. The method of claim 15, wherein the antisense oligo-
nucleotide comprises a sequencethat is substantially comple-
mentary to SEQ ID NO: 1 or SEQ ID NO:2.
17. The method of claim 15, wherein the antisense oligo-
nucleotide comprises at least one sugar and/or backbone
modification.
18. The method of claim 17, wherein the sugar modifica-
tion is a locked nucleic acid.
19. The method of claim 17, wherein the backbone modi-
fication is a phosphorothioate linkage.
20. The method of claim 15, wherein the antisense oligo-
nucleotide is about 7 to about 18 nucleotides in length.
21. The method of claim 15, wherein the antisense oligo-
nucleotide has a sequence selected from the group consisting
10
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ofSEQ ID NO: 7, SEQIDNO: 8, SEQIDNO: 9, SEQID NO:
10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO:13, SEQ
IDNO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO:17,
SEQ ID NO:18, SEQ ID NO: 19, SEQ ID NO:20, SEQ ID
NO:21, and SEQ ID NO:22.
22. The methodofclaim 12, wherein the subject is human.
23. The method ofclaim 12, wherein the inhibitor is admin-
istered to the subject by an intradermal, subcutaneous,intra-
muscular, intraperitoneal or intravenous route of administra-
tion.
24. A methodofregulating fatty acid metabolism in acell
comprising contacting the cell with a modulator ofmiR-378
and/or miR-378* expression or activity, wherein said modu-
lator is an inhibitor ofmiR-378 and/or miR-378* expression
or activity, and wherein said inhibitor is an antisense oligo-
nucleotide.
25. The method ofclaim 24, wherein fatty acid metabolism
is increased in the cell following contact with the miR-378
and/or miR-378* inhibitor as comparedto a cell not exposed
to the inhibitor.
26. The method of claim 24, wherein the antisense oligo-
nucleotide comprises a sequencethat is substantially comple-
mentary to a mature sequence ofmiR-378 and/or miR-378*.
27. The method of claim 26, wherein the antisense oligo-
nucleotide comprises at least one sugar and/or backbone
modification.
28. The method of claim 27, wherein the sugar modifica-
tion is a locked nucleic acid.
29. The method of claim 27, wherein the backbone modi-
fication is a phosphorothioate linkage.
30. The methodof claim 26, wherein the antisense oligo-
nucleotide is about 7 to about 18 nucleotides in length.
31. The method of claim 24, wherein the cell is a cardi-
omyocyte, a skeletal muscle cell, a preadipocyte, or an adi-
pocyte.
32. The methodof claim 24, wherein thecell is in vitro or
in Vivo.
